1. Anaflous A, Benchat N, Mimouni M, Abouricha S, Ben Hadda T, El-Bali B, Hakkou A, Hacht B (2004) Armed imidazo [1,2-a] pyrimidines (pyridines): evaluation of antibacterial activity. Lett Drug Des Discov 1:224–229
2. Ben Hadda T, Benchat N, El-Bali B, Abouricha S, Moueqqit M, Mimouni M (2003) Impact of dimroth rearrangement on anti-tuberculosis activity of 3-armed-imidazo[1.2-a]pyrimidines IMP (-pyridines) IP. Med Pharm Chem 0301001:1–18
3. Ben Hadda T, Kotchevar AT, Daoudi M, Bennani B, Larbi NB, Kerbal A (2005) Anti-tumour activity of some polydentate N-ligands: N,N-bis-(3-substituted-5-methylpyrazol-1yl methyl)arylamines and N,N,N′,N′-tetra-[(3-substituted-5-methylpyrazol-1yl] para-phenylenediamines. Lett Drug Des Discov 2:584–589
4. Ben Hadda T, Badri R, Kerbal A, Baba BF, Akkurt M, Demailly G, Benazza M (2007) Synthesis and antitubercular activity of spiroheterocycles: 2,2′,4′,5′-tetra-substituted-1,2,2′,4′-tetrahydro-4H-spiro[isoquinoline-3,3′-pyrazol]-4-ones. Arkivoc XIV:276–288
5. Ben Hadda T, Rahima B, Kerbal A, Baba BF, Akkurt M, Demailly G, Benazza M (2008) Looking for a new antitubercular pharmacophore site: synthesis and bioactivity of spiroheterocycles 2,3′,4′-tri-subsituted-1,2-dihydro-4H,4′H-spiro[iso-quinoline-3,5′-isoxazol]-4-ones. Arkivoc ii:1–13